Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference

15.1.2026 01:40:00 CET | Business Wire | Press Release

Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/

Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings

"2026 is a monumental year for us, as we enter into a new chapter for our company. Today, we are announcing six additional candidates in our biosimilar pipeline, including vedolizumab and dupilumab. We are making great progress to secure 20 biosimilars in our portfolio by 2030," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We also received the investigational new drug application (IND) clearance for the first novel therapeutic candidate developed by Samsung Bioepis, and plan to advance our clinical program this year. As we broaden our portfolio beyond biosimilars, we will continue our development efforts in antibody-drug conjugates (ADCs), leveraging our innovative research and development platform to expand viable treatment options for patients with unmet needs.”

Samsung Bioepis Biosimilar Updates

Samsung Bioepis currently has 11 biosimilars for 10 unique biological molecules approved and launched in more than 40 countries.¹ The company has pembrolizumab biosimilar undergoing Phase 1 and 3 clinical studies, and plans to secure 20 biosimilars in its portfolio by 2030.
The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab.

Novel Therapeutics Updates

In December 2025, the FDA has cleared the IND Application for SBE303. SBE303 is Samsung Bioepis’ first novel ADC engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.² The Phase 1 first-in-human clinical trial, aiming to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of SBE303 in participants with advanced refractory solid tumors, is set to begin this year.
Samsung Bioepis plans to have one novel therapeutic candidate enter into clinical study every year.
Epis NexLab, the new subsidiary under Samsung Epis Holdings, has launched a project to develop a peptide-based drug delivery platform.

Samsung Bioepis Biosimilars Portfolio

Code Name (Brand Name³)	Non-proprietary Name	Reference Product	Status⁴
SB5 (IMRALDI™, HADLIMA™, ADALLOCE™)	Adalimumab	Humira	Launch
SB4 (BENEPALI™, BRENZYS™, ETOLOCE™)	Etanercept	Enbrel	Launch
SB2 (FLIXABI™, RENFLEXIS™, REMALOCE™)	Infliximab	Remicade	Launch
SB3 (ONTRUZANT™, SAMFENET™)	Trastuzumab	Herceptin	Launch
SB8 (AYBINTIO™)	Bevacizumab	Avastin	Launch
SB11 (BYOOVIZ™, AMELIVU™)	Ranibizumab	Lucentis	Launch
SB12 (EPYSQLI™)	Eculizumab	Soliris	Launch
SB15 (OPUVIZ™, AFILIVU™)	Aflibercept	Eylea	Launch
SB16 (OBODENCE™, OSPOMYV™)	Denosumab	Prolia	Launch
SB16 (XBRYK™)	Denosumab	Xgeva	Launch
SB17 (PYZCHIVA™, EPYZTEK™)	Ustekinumab	Stelara	Launch
SB27	Pembrolizumab	Keytruda	Phase 1 and 3

Samsung Bioepis Biosimilar Candidates in Early Stage Development

Non-proprietary Name	Reference Product
Dupilumab	Dupixent
Guselkumab	Tremfya
Ixekizumab	Taltz
Vedolizumab	Entyvio
Ocrelizumab	Ocrevus
Fam-trastuzumab deruxtecan-nxki	Enhertu

About Samsung Epis Holdings Co., Ltd.

As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value through proactive R&D and investment and optimize business strategies for its subsidiaries, Samsung Bioepis and Epis NexLab. Samsung Epis Holdings continues to embrace future challenges and drive innovation by identifying new growth drivers and strengthening global collaboration platforms, thereby laying a solid foundation for the continued growth of its subsidiaries. For more information about Samsung Epis Holdings, please visit: www.samsungepisholdings.com.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

About Epis NexLab Co., Ltd.

Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab is focused on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Epis NexLab, please visit: www.samsungepisholdings.com.

¹ “more than 40 countries” signifies countries where Samsung Bioepis has commercial presence, with one or more products.
² Li K, Zhou Y, Zang M, Jin X, Li X. Therapeutic prospects of nectin-4 in cancer: applications and value. Front Oncol. 2024 Mar 28;14:1354543. doi: 10.3389/fonc.2024.1354543. PMID: 38606099; PMCID: PMC11007101.
³ Different brand names for different regions and countries.
⁴ “Launch” signifies launch in one or more markets and does not necessarily indicate launch in all markets worldwide

View source version on businesswire.com: https://www.businesswire.com/news/home/20260114206458/en/

Contacts

Media Contact
Anna Nayun Kim, nayun86.kim@samsung.com
Yoon Kim, yoon1.kim@samsung.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kao’s Laurier Launches New Brand Communication Initiative across Asia: Strengthening Global Integration as a Core Brand in Kao’s Asian Business4.3.2026 03:10:00 CET | Press Release

Starting on International Women’s Day, March 8, Kao Corporation (TOKYO:4452) will launch new brand communication campaign in nine Asian countries and regions for its feminine sanitary product brand, Laurier, which is the core of its Asian business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303996141/en/ Laurier Campaign Key Visual Laurier aims to help create more supportive and understanding environments around menstruation, so that women can feel more at ease, both physically and emotionally, under the key message “Comfort, Made Together,” which will be implemented simultaneously across Asia. Kao aims to further develop Laurier as a global brand. Laurier, one of the core brands supporting Kao’s consumer care business in Asia, has been promoting globally integrated operations since 2023. Across all nine Asian countries and regions including Japan, Laurier has been working to unify product specifications and consolida

FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World ...3.3.2026 23:06:00 CET | Press Release

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303105064/en/ FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World Cup 2026™ FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World Cup 2026™ On Tuesday, March 3, the Empire State Building will rotate in the colors of the flags of the three host countries – the United States, Canada, and Mexico – to mark 100 days to go until the FIFA World Cup 2026™. Earlier today, the Empire State Building hosted a special tower lighting ceremony with Alex Lasry, CEO of the FIFA World Cup 26™ New York New Jersey Host C

SES Publishes 2025 Annual Report3.3.2026 21:41:00 CET | Press Release

SES S.A. has today published its 2025 Annual Report, following the announcement of the company’s full year financial results for the 12 months ended 31 December 2025. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry leadership—backed by a track record of bringing innovation “firsts” to market. As a trusted partner to customers and the global space ecosystem, SES is driving impact that goes far beyond coverage. The company is headquartered

Xsolla Expands Global Payment Coverage Across 18 Markets With 6 Trusted Local Payment Methods to Help Developers Reach New Players Worldwide3.3.2026 18:00:00 CET | Press Release

Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced a major expansion of its global payments portfolio across 18 markets in Europe, the Middle East, Africa, and Asia. As developers continue to expand into high-growth and emerging markets, this expansion enables developers to reach new paying users, improve conversion rates, and deliver payment experiences tailored to local player preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303816373/en/ Graphic: Xsolla The newly supported payment methods include: Local Amazon Pay in Japan, with over 100 million registered Amazon Japan accounts, provides fully localized checkout experiences in Japanese Yen Zain Cash in Iraq is expanding access to mobile-first payment options in a rapidly growing economy, where mobile numbers serve as primary digital identities and mobile adoption is broad across a popula

SES Announces Annual General Meeting of Shareholders3.3.2026 17:42:00 CET | Press Release

SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Annual General Meeting of SES, Société Anonyme, to be held at the Company’s registered office at Château de Betzdorf, L-6815 Betzdorf (the “Company”), Luxembourg, on Thursday 2 April 2026 at 10:30 a.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Presentation by the Chairman of the Board of Directors of the 2025 activities report of the Board of Directors Presentation of the main developments during 2025 and of the outlook Presentation of the audit report Approval of annual financial statements, balance sheet and profit and loss account as of 31 December 2025 Approval of consolidated financial statements as of 31 December 2025 Allocation of 2025 profits and transfers between reserve accounts Discharge of the members of the Board of Directors Determination of the number of Directors Confirmation of the co-optation of Joseph Cohen and determination o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom